Establishing and Validating a novel Prognostic Model in the Initial Diagnosis of Non-small Cell Lung Cancer with Bone Metastases
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new prognostic model accurately predicts outcomes for non-small cell lung cancer (NSCLC) patients with bone metastases, outperforming existing methods and aiding personalized treatment strategies.
Area Of Science
- Oncology
- Medical Statistics
Background
- Non-small cell lung cancer (NSCLC) with bone metastases presents a significant challenge in prognosis prediction.
- Accurate prognostic tools are crucial for guiding treatment decisions in these patients.
Purpose Of The Study
- To develop and validate a novel prognostic model for predicting survival in NSCLC patients with bone metastases.
- To compare the model's performance against the advanced lung cancer inflammation index (ALI).
Main Methods
- Retrospective analysis of 176 NSCLC patients with bone metastases.
- Utilized LASSO-Cox regression for indicator selection and prognostic model construction.
- Assessed model discriminative ability using ROC curves and C-index.
Main Results
- A 9-indicator prognostic model was established, demonstrating superior C-index values in both training (0.738) and validation (0.660) cohorts compared to ALI.
- The model achieved higher AUCs for 1-, 2-, and 3-year overall survival (OS) predictions than ALI.
- Risk stratification identified subgroups with significantly different cancer-specific mortality probabilities.
Conclusions
- The developed prognostic model offers precise prognostic information for NSCLC patients with bone metastases.
- Facilitates individualized treatment planning and improves clinical decision-making for this patient population.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.